Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2536 to 2550 of 7711 results

  1. Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]

    Awaiting development [GID-TA11663] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Kidney Cancer

    In development [GID-NG10398] Expected publication date: TBC

    NICE guideline
    In development

  3. Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour

    In development [GID-IPG10408] Expected publication date: 16 April 2025

    Interventional procedures guidance
    In development

  4. Triheptanoin for treating long-chain fatty acid oxidation disorders ID3891

    Awaiting development [GID-TA11473] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]

    In development [GID-TA11197] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]

    In development [GID-TA11496] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  7. Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423

    In development [GID-TA11431] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  8. Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

    In development [GID-TA10990] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  9. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development [GID-TA11096] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathway

    In development [GID-HTE10047] Expected publication date: TBC

    Health technology evaluations
    In development

  11. Type 2 diabetes in adults: management (medicines update)

    In development [GID-NG10336] Expected publication date: 30 July 2025

    NICE guideline
    In development

  12. Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]

    Awaiting development [GID-TA11440] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210]

    Awaiting development [GID-TA11182] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]

    Awaiting development [GID-TA11214] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease ID6459

    In development [GID-TA11572] Expected publication date: TBC

    Technology appraisal guidance
    In development